ATHA
Income statement / Annual
Last year (2024), Athira Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Athira Pharma, Inc.'s net income was -$96.94 M.
See Athira Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$479.00 K
|
$2.00 M
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$479.00 K
|
-$2.00 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$70.68 M
|
$93.79 M
|
$61.46 M
|
$42.79 M
|
$13.29 M
|
$3.79 M
|
$3.59 M
|
| General & Administrative Expenses |
$26.09 M
|
$33.30 M
|
$32.55 M
|
$21.23 M
|
$6.71 M
|
$1.66 M
|
$1.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.09 M
|
$33.30 M
|
$32.55 M
|
$21.23 M
|
$6.71 M
|
$1.66 M
|
$1.42 M
|
| Other Expenses |
$4.13 M
|
-$1.63 M
|
$10.00 M
|
-$479.00 K
|
-$2.00 M
|
-$754.00 K
|
$0.00
|
| Operating Expenses |
$100.90 M
|
$125.47 M
|
$104.02 M
|
$63.54 M
|
$18.00 M
|
$4.70 M
|
$5.01 M
|
| Cost And Expenses |
$100.90 M
|
$125.47 M
|
$104.02 M
|
$64.02 M
|
$20.00 M
|
$4.70 M
|
$5.01 M
|
| Interest Income |
$3.96 M
|
$7.64 M
|
$3.22 M
|
$337.00 K
|
$124.00 K
|
$51.00 K
|
$85.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$24.32 M
|
$3.00 K
|
$367.00 K
|
$346.00 K
|
$9.00 K
|
| Depreciation & Amortization |
$970.00 K
|
$969.00 K
|
$845.00 K
|
$479.00 K
|
$2.00 K
|
$2.00 K
|
$5.01 M
|
| EBITDA |
-$95.81 M |
-$125.97 M |
-$88.01 M |
-$54.37 M |
-$19.59 M |
-$4.81 M |
-$79.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.96 M
|
$7.79 M
|
$8.38 M
|
$9.17 M
|
$40.00 K
|
$288.00 K
|
-$88.00 K
|
| Income Before Tax |
-$96.94 M
|
-$117.67 M
|
-$95.64 M
|
-$54.85 M
|
-$19.96 M
|
-$5.16 M
|
-$5.10 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$96.94 M
|
-$117.67 M
|
-$95.64 M
|
-$54.85 M
|
-$19.96 M
|
-$5.16 M
|
-$5.10 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-25.2 |
-30.9 |
-25.3 |
-14.9 |
-6.1 |
-1.4 |
-1.6 |
| EPS Diluted |
-25.2 |
-30.9 |
-25.3 |
-14.9 |
-6.1 |
-1.4 |
-1.6 |
| Weighted Average Shares Out |
$3.85 M
|
$3.80 M
|
$3.77 M
|
$3.69 M
|
$3.25 M
|
$3.26 M
|
$3.26 M
|
| Weighted Average Shares Out Diluted |
$3.85 M
|
$3.80 M
|
$3.77 M
|
$3.69 M
|
$3.25 M
|
$3.26 M
|
$3.26 M
|
| Link |
|
|
|
|
|
|
|
